GCLC公司
KEAP1型
MG132型
癌症研究
癌细胞
癌症
GCLM公司
肺癌
蛋白酶体抑制剂
生物
细胞生长
蛋白酶体
下调和上调
细胞生物学
医学
转录因子
生物化学
基因
内科学
遗传学
作者
Di Zhang,Zhilin Hou,Kelly E. Aldrich,Lizbeth Lockwood,Aaron L. Odom,Karen T. Liby
出处
期刊:Molecular Cancer Therapeutics
[American Association for Cancer Research]
日期:2021-06-22
卷期号:20 (9): 1692-1701
被引量:26
标识
DOI:10.1158/1535-7163.mct-21-0210
摘要
Abstract The nuclear factor erythroid-2-related factor 2 (Nrf2)–Keap1–ARE pathway, a master regulator of oxidative stress, has emerged as a promising target for cancer therapy. Mutations in NFE2L2, KEAP1, and related genes have been found in many human cancers, especially lung cancer. These mutations lead to constitutive activation of the Nrf2 pathway, which promotes proliferation of cancer cells and their resistance to chemotherapies. Small molecules that inhibit the Nrf2 pathway are needed to arrest tumor growth and overcome chemoresistance in Nrf2-addicted cancers. Here, we identified a novel small molecule, MSU38225, which can suppress Nrf2 pathway activity. MSU38225 downregulates Nrf2 transcriptional activity and decreases the expression of Nrf2 downstream targets, including NQO1, GCLC, GCLM, AKR1C2, and UGT1A6. MSU38225 strikingly decreases the protein level of Nrf2, which can be blocked by the proteasome inhibitor MG132. Ubiquitination of Nrf2 is enhanced following treatment with MSU38225. By inhibiting production of antioxidants, MSU38225 increases the level of reactive oxygen species (ROS) when cells are stimulated with tert-butyl hydroperoxide (tBHP). MSU38225 also inhibits the growth of human lung cancer cells in both two-dimensional cell culture and soft agar. Cancer cells addicted to Nrf2 are more susceptible to MSU38225 for suppression of cell proliferation. MSU38225 also sensitizes human lung cancer cells to chemotherapies both in vitro and in vivo. Our results suggest that MSU38225 is a novel Nrf2 pathway inhibitor that could potentially serve as an adjuvant therapy to enhance the response to chemotherapies in patients with lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI